BR112017011923A2 - bactéria modificada para tratar doenças associadas com hiperamonemia - Google Patents
bactéria modificada para tratar doenças associadas com hiperamonemiaInfo
- Publication number
- BR112017011923A2 BR112017011923A2 BR112017011923A BR112017011923A BR112017011923A2 BR 112017011923 A2 BR112017011923 A2 BR 112017011923A2 BR 112017011923 A BR112017011923 A BR 112017011923A BR 112017011923 A BR112017011923 A BR 112017011923A BR 112017011923 A2 BR112017011923 A2 BR 112017011923A2
- Authority
- BR
- Brazil
- Prior art keywords
- hyperammonemia
- diseases associated
- treat diseases
- bacteria modified
- bacteria
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/10—Citrulline; Arginine; Ornithine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
- C12Y203/01001—Amino-acid N-acetyltransferase (2.3.1.1)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462087854P | 2014-12-05 | 2014-12-05 | |
| US201562103513P | 2015-01-14 | 2015-01-14 | |
| US201562150508P | 2015-04-21 | 2015-04-21 | |
| US201562173710P | 2015-06-10 | 2015-06-10 | |
| US201562173706P | 2015-06-10 | 2015-06-10 | |
| US201562183935P | 2015-06-24 | 2015-06-24 | |
| US201562184811P | 2015-06-25 | 2015-06-25 | |
| US201562256039P | 2015-11-16 | 2015-11-16 | |
| US201562256041P | 2015-11-16 | 2015-11-16 | |
| US201562263329P | 2015-12-04 | 2015-12-04 | |
| PCT/US2015/064140 WO2016090343A1 (en) | 2014-12-05 | 2015-12-04 | Bacteria engineered to treat diseases associated with hyperammonemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017011923A2 true BR112017011923A2 (pt) | 2018-02-27 |
Family
ID=55022714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017011923A BR112017011923A2 (pt) | 2014-12-05 | 2015-12-04 | bactéria modificada para tratar doenças associadas com hiperamonemia |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9487764B2 (https=) |
| JP (1) | JP6768689B2 (https=) |
| KR (1) | KR102493174B1 (https=) |
| AU (1) | AU2015357549B2 (https=) |
| BR (1) | BR112017011923A2 (https=) |
| CA (1) | CA2969724A1 (https=) |
| IL (2) | IL252627B (https=) |
| MX (2) | MX383245B (https=) |
| SG (2) | SG11201704543XA (https=) |
| WO (1) | WO2016090343A1 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201704543XA (en) * | 2014-12-05 | 2017-07-28 | Synlogic Inc | Bacteria engineered to treat diseases associated with hyperammonemia |
| US9688967B2 (en) | 2014-12-05 | 2017-06-27 | Synlogic, Inc. | Bacteria engineered to treat diseases associated with hyperammonemia |
| US10610546B2 (en) * | 2015-05-13 | 2020-04-07 | Synlogic Operating Company Inc. | Bacteria engineered to reduce hyperphenylalaninemia |
| US20160206666A1 (en) | 2014-12-22 | 2016-07-21 | Synlogic, Inc. | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier |
| US11883439B2 (en) | 2015-05-13 | 2024-01-30 | Synlogic Operating Company, Inc. | Bacteria engineered to treat a disease or disorder |
| WO2016210384A2 (en) | 2015-06-25 | 2016-12-29 | Synlogic, Inc. | Bacteria engineered to treat metabolic diseases |
| US11685925B2 (en) | 2015-10-30 | 2023-06-27 | Synlogic Operating Company, Inc. | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier |
| WO2017123675A1 (en) | 2016-01-11 | 2017-07-20 | Synlogic, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
| WO2017139708A1 (en) | 2016-02-10 | 2017-08-17 | Synlogic, Inc. | Bacteria engineered to treat nonalcoholic steatohepatitis (nash) |
| AU2017252409B2 (en) | 2016-04-20 | 2023-08-24 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for nucleic acid expression and protein secretion in bacteroides |
| WO2018112194A1 (en) | 2016-12-15 | 2018-06-21 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for modulating growth of a genetically modified gut bacterial cell |
| JP2020505016A (ja) | 2017-01-06 | 2020-02-20 | シンロジック オペレーティング カンパニー インコーポレイテッド | 腫瘍細胞において免疫モジュレーターおよび抗がん治療剤を産生するようにプログラムされた微生物 |
| JP2020516318A (ja) * | 2017-04-17 | 2020-06-11 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 操作された共生細菌及び使用方法 |
| CN111655841A (zh) | 2017-06-21 | 2020-09-11 | 同生运营公司 | 用于治疗紊乱的细菌 |
| EP3648769A4 (en) * | 2017-06-30 | 2021-04-07 | The Rockefeller University | HUMAN INTESTINAL FLORA-DERIVED N-ACYLAMIDES FOR THE TREATMENT OF HUMAN DISEASES |
| CN111246865A (zh) * | 2017-07-12 | 2020-06-05 | 同生运营公司 | 程序化以在肿瘤细胞中产生免疫调节剂和抗癌治疗剂的微生物 |
| EP3703705B1 (en) | 2017-11-03 | 2024-05-15 | DSM Nutritional Products, LLC | Glucose-containing glycan preparations for use in the treatment of hyperammonaemia |
| JP7460531B2 (ja) | 2017-12-05 | 2024-04-02 | バイオピーエルエックス，インコーポレイティド | 微生物感染を防ぐための方法および組成物 |
| CA3088630A1 (en) | 2017-12-15 | 2019-06-20 | Solarea Bio, Inc. | Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome |
| JP2021525760A (ja) | 2018-06-02 | 2021-09-27 | シンロジック オペレーティング カンパニー インコーポレイテッド | 肝疾患を処置するように操作された細菌 |
| CA3109600A1 (en) | 2018-08-21 | 2020-02-27 | Kaleido Biosciences, Inc. | Oligosaccharide compositions and methods of use thereof for reducing ammonia levels |
| US11980647B2 (en) | 2018-09-05 | 2024-05-14 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause |
| CA3111795A1 (en) | 2018-09-05 | 2020-03-12 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases |
| CN113260635B (zh) | 2018-11-08 | 2023-10-31 | Dsm营养产品有限责任公司 | 寡糖组合物及其使用方法 |
| WO2020223345A1 (en) | 2019-04-29 | 2020-11-05 | Antipov Eugene | Enumeration of genetically engineered microorganisms by live cell counting techniques |
| WO2020237246A1 (en) * | 2019-05-23 | 2020-11-26 | University Of Maryland, Baltimore | Live attenuated non-transmissible vaccines |
| AU2020288624B2 (en) | 2019-06-04 | 2025-09-25 | Cocoon Biotech Inc. | Silk-based products, formulations, and methods of use |
| WO2021107500A1 (ko) | 2019-11-29 | 2021-06-03 | 주식회사 지니스 | 혈중 암모니아 수치 저하능을 갖는 균주 및 이를 포함하는 신경세포 보호용 조성물 |
| CN112924607A (zh) * | 2019-12-05 | 2021-06-08 | 湖北远大生物技术有限公司 | 一种同时检测酶促反应液中α-酮戊二酸和L-谷氨酸的方法 |
| CN115298308A (zh) | 2020-03-20 | 2022-11-04 | 同生运营公司 | 经工程化以减轻高苯丙氨酸血症的微生物 |
| WO2022120028A2 (en) | 2020-12-02 | 2022-06-09 | Synlogic Operating Company, Inc. | Engineered microorganisms |
| IL304020A (en) * | 2020-12-30 | 2023-08-01 | Eligo Bioscience | Microbiome modulation of a host by delivery of dna payloads with minimized spread |
| EP4436407A1 (en) | 2021-11-22 | 2024-10-02 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause |
| US20230190834A1 (en) | 2021-12-21 | 2023-06-22 | Solarea Bio, Inc. | Immunomodulatory compositions comprising microbial entities |
| KR102853096B1 (ko) * | 2022-03-18 | 2025-09-02 | 씨제이제일제당 주식회사 | 카르바모일 인산 합성효소의 활성이 약화된 l-아미노산을 생산하는 미생물 및 이를 이용한 l-아미노산 생산 방법 |
| CN115960807A (zh) * | 2022-11-29 | 2023-04-14 | 深圳先进技术研究院 | 一种厌氧高产l-精氨酸工程菌及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9107305D0 (en) | 1991-04-08 | 1991-05-22 | Unilever Plc | Probiotic |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| US6203797B1 (en) | 1998-01-06 | 2001-03-20 | Stephen C. Perry | Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome |
| EP1135461A4 (en) | 1998-12-02 | 2003-03-26 | Univ Boston | GEN NETWORKS FOR CONTROLLING GENE EXPRESSION |
| EP1034787A1 (en) | 1999-03-11 | 2000-09-13 | Société des Produits Nestlé S.A. | Lactobacillus strains preventing diarrhea caused by pathogenic bacteria |
| JP4682454B2 (ja) * | 2000-06-28 | 2011-05-11 | 味の素株式会社 | 新規変異型ｎ−アセチルグルタミン酸合成酵素及びｌ−アルギニンの製造法 |
| DE10101793A1 (de) * | 2001-01-17 | 2002-08-01 | Manfred Nilius | Verwendung von SLPI zur Behandlung chronisch-entzündlicher Darmerkrankungen |
| US7731976B2 (en) | 2003-08-29 | 2010-06-08 | Cobb And Company, Llp | Treatment of irritable bowel syndrome using probiotic composition |
| BRPI0516176B1 (pt) * | 2004-09-28 | 2020-12-29 | Kyowa Hakko Bio Co., Ltd. | Polipeptídeo, dna, microorganismo, e, processo para produzir l-arginina, l-ornitina ou lcitrulina |
| SG11201704543XA (en) * | 2014-12-05 | 2017-07-28 | Synlogic Inc | Bacteria engineered to treat diseases associated with hyperammonemia |
-
2015
- 2015-12-04 SG SG11201704543XA patent/SG11201704543XA/en unknown
- 2015-12-04 WO PCT/US2015/064140 patent/WO2016090343A1/en not_active Ceased
- 2015-12-04 SG SG10202010444UA patent/SG10202010444UA/en unknown
- 2015-12-04 AU AU2015357549A patent/AU2015357549B2/en not_active Ceased
- 2015-12-04 US US14/960,333 patent/US9487764B2/en active Active
- 2015-12-04 BR BR112017011923A patent/BR112017011923A2/pt not_active Application Discontinuation
- 2015-12-04 JP JP2017548375A patent/JP6768689B2/ja not_active Expired - Fee Related
- 2015-12-04 KR KR1020177018338A patent/KR102493174B1/ko active Active
- 2015-12-04 MX MX2017007148A patent/MX383245B/es unknown
- 2015-12-04 CA CA2969724A patent/CA2969724A1/en not_active Abandoned
-
2017
- 2017-06-01 IL IL252627A patent/IL252627B/en active IP Right Grant
- 2017-06-05 MX MX2021006581A patent/MX2021006581A/es unknown
-
2020
- 2020-10-19 IL IL278150A patent/IL278150A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102493174B1 (ko) | 2023-01-27 |
| AU2015357549B2 (en) | 2022-03-24 |
| KR20170097078A (ko) | 2017-08-25 |
| AU2015357549A1 (en) | 2017-06-29 |
| IL252627B (en) | 2020-11-30 |
| IL278150A (en) | 2020-11-30 |
| WO2016090343A1 (en) | 2016-06-09 |
| JP6768689B2 (ja) | 2020-10-14 |
| CA2969724A1 (en) | 2016-06-09 |
| SG10202010444UA (en) | 2020-11-27 |
| MX383245B (es) | 2025-03-13 |
| MX2017007148A (es) | 2017-10-11 |
| JP2018504919A (ja) | 2018-02-22 |
| WO2016090343A9 (en) | 2016-09-09 |
| IL252627A0 (en) | 2017-07-31 |
| US9487764B2 (en) | 2016-11-08 |
| US20160177274A1 (en) | 2016-06-23 |
| MX2021006581A (es) | 2021-07-15 |
| SG11201704543XA (en) | 2017-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017011923A2 (pt) | bactéria modificada para tratar doenças associadas com hiperamonemia | |
| BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
| MX385332B (es) | Moduladores de ror-gamma. | |
| MX391981B (es) | Derivados de benzooxazol como inmunomoduladores. | |
| MX392026B (es) | Compuestos heterocíclicos como inmunomoduladores. | |
| EA201990665A1 (ru) | Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака | |
| MX389513B (es) | Compuestos heterocíclicos como inmunomoduladores. | |
| MX2017013562A (es) | Reguladores de microbioma y usos relacionados de los mismos. | |
| EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
| BR112014021104A2 (pt) | métodos e composições para o tratamento da doença de huntington | |
| WO2016200614A3 (en) | Bacteria engineered to treat diseases associated with hyperammonemia | |
| MX376835B (es) | Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos. | |
| BR112017003111A2 (pt) | composições e métodos para o tratamento de distúrbios neurológicos | |
| EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
| MX390120B (es) | Moduladores de la somatostatina y usos de los mismos. | |
| MX381313B (es) | Derivados de benzimidazol como moduladores de ror-gamma | |
| WO2017136795A8 (en) | Bacteria engineered to treat diseases associated with tryptophan metabolism | |
| WO2016183532A8 (en) | Bacteria engineered to treat a disease or disorder | |
| WO2017139697A8 (en) | Bacteria engineered to treat diseases associated with hyperammonemia | |
| PH12017501095A1 (en) | Piperidine derivatives as hdac1/2 inhibitors | |
| PL410665A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| EA201692313A1 (ru) | Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ | |
| BR112014027981A2 (pt) | compostos do tipo fumagilol e métodos de produção e utilização dos mesmos | |
| PH12018500315A1 (en) | Fumagillol heterocyclic compounds and methods of making and using same | |
| MX2019001634A (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: SYNLOGIC OPERATING COMPANY, INC. (US) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |